Servier is the leading French independent pharmaceutical company, present in 140 countries with 20 000 employees and a turnover for 2011 of 3.9 billion euros. 25% of Servier’s annual turnover is reinvested in Research & Development, reflecting the company’s dedication to its research mission of innovation and discovery to treat unmet medical needs. There are no shareholders, and no dividends are distributed from Servier’s turnover. The main therapeutic areas for which Servier’s research is renowned are cancer, cardiovascular disease, endocrinology, neuroscience, rheumatology, and venous disease. 30 innovative medicines have been developed from in-house research since the company’s beginnings in 1954, the last three of which are each first of their therapeutic class. Servier is currently collaborating with approximately 30 public and private research organizations throughout the world, including many biotech companies who chose to work with Servier among a large number of candidate companies. 68% of Servier’s medicines are produced in France. As 90% of Servier medicines are consumed outside France, Servier thus contributes 64.2% of the positive commercial balance in favor of exportation in the pharmaceutical sector in France. Servier is reputed for staff care, with particular attention to career evolution within the group such that staff turnover at Servier is significantly lower than the national average.